## 510 (k) SUMMARY AS REQUIRED BY SECTION 807.92(C)

Identification: InstaCheck® Multi-Drug Screen Panels:

1. 810C, THC/COC/PCP, MOR 2000/AMP, BAR/BZO/MTD Test

2. 812C, THC/COC/PCP, MOR 300/AMP, BAR/BZO/MTD Test

3. 835C, THC/COC/PCP, MOR 2000/MET, BAR/BZO/MTD Test

4. 837C, THC/COC/PCP, MOR 300/MET, BAR/BZO/MTD Test

5. 712C, THC/COC/PCP, MOR 300, BAR/BZO/MTD Test

**Description**: One-step, colloidal gold based chromatographic immunoassay for the rapid, qualitative detection of THC, Cocaine, PCP, Morphine, Amphetamine, Methamphetamine, Barbiturates, Benzodiazepines and Methadone in urine.

Name of Manufacturer:


Forefront Diagnostics, Inc. 23561 Ridge Route Dr. Suite D Laguna Hills, CA 92653

Intended Use: The Forefront Diagnostics InstaCheck<sup>®</sup> Multi-Drug Screen Panels are *in vitro* screen tests for the rapid detection of target drugs/metabolites in urine. The cut-off concentration for these tests is as follows: THC (11-nor-Δ<sup>9</sup>-Tetrahydrocannabinol-9-carboxylic acid): 50ng/ml, Cocaine (Benzoylecgonine): 300 ng/ml, PCP: 25 ng/ml, Morphine: 300 or 2000 ng/ml, Amphetamine: 1000 ng/ml, Methamphetamine: 1000 ng/ml, Barbiturates (Secobarbital): 300 ng/ml, Benzodiazepines (Oxazepam): 300 ng/ml and Methadone: 300 ng/ml. The test kit is used to obtain a visual, qualitative result and is intended for professional use. It is not intended for over the counter sale to lay persons.

Technology: The InstaCheck<sup>®</sup> Multi-Drug Screen Panels, like multi-drug tests from other manufacturers such as Roche, American Biotech Inc, etc. as well as currently marketed Drug Screen Single Test "predicate" devices, qualitatively measure the presence of target drugs or their metabolites by visual color sandwich one step immunoassay technology. Our currently marketed InstaCheck<sup>®</sup> Drug Screen Single Test Panels are used for substantial equivalence predicate kit because other manufacturers' multi-drug tests use different drug combinations compared with our InstaCheck<sup>®</sup> Multi-Drug Screen Panels. All of these products are based on the same immunochemical principle of recognition and formation of specific antibody / target drug / antibody / complexes.

Performance: The product performance characteristics of InstaCheck<sup>®</sup> Multi-Drug Screen Panels were evaluated in a blind-labeled spiked control study and in a blind-labeled clinical specimen correlation study. The results of these studies demonstrate the InstaCheck<sup>®</sup> Multi-Drug Screen Panels to be substantially equivalent to the performance characteristics of the InstaCheck<sup>®</sup> Drug Screen Single Test panels, which have received 510(k) approvals. Correlation studies, using clinical specimens, produced a >96% correlation when compared to GC/MS methodology. Clinical site studies, performed at Forefront Diagnostics, Inc and two independent laboratories, were also performed. The results of this study demonstrated that the InstaCheck<sup>®</sup> Multi-Drug Screen Panels can be performed by professional and laboratory personnel to obtain a visual, qualitative, rapid detection of drugs of abuse and its metabolite.

Conclusion: For the reasons mentioned above, it may be concluded that InstaCheck® Multi-Drug Screen Panels are substantially equivalent to the InstaCheck® Drug Screen Single Test Panels presently distributed commercially.



## MAR - 7 2001

Food and Drug Administration 2098 Gaither Road Rockville MD 20850

Mr. Feng-Yu Lee Vice President of Quality System Forefront Diagnostics, Inc. 23561 Ridge Route Drive Suite D Laguna Hills, California 92653

Re:

K003106

Trade Names: InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 2000/AMP,

BAR/BZO/MTD Test

InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/AMP,

BAR/BZO/MTD Test

InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 2000/MET,

BAR/BZO/MTD Test

InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/MET,

BAR/BZO/MTD Test

InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300,

BAR/BZO/MTD Test

Regulatory Class: II

Product Code: DKZ, LAF, DIO, DJG, LDJ, DJR, LCM, DIS, JXM

Dated: January 8, 2001 Received: February 22, 2001

Dear Mr. Lee:

We have reviewed your Section 510(k) notification of intent to market the device referenced above and we have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

## Page 2

If your device is classified (see above) into either class II (Special Controls) or class III (Premarket Approval), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 895. A substantially equivalent determination assumes compliance with the Current Good Manufacturing Practice requirements, as set forth in the Quality System Regulation (QS) for Medical Devices: General regulation (21 CFR Part 820) and that, through periodic QS inspections, the Food and Drug Administration (FDA) will verify such assumptions. Failure to comply with the GMP regulation may result in regulatory action. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please note: this response to your premarket notification submission does not affect any obligation you might have under sections 531 through 542 of the Act for devices under the Electronic Product Radiation Control provisions, or other Federal laws or regulations.

This letter will allow you to begin marketing your device as described in your 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and additionally 809.10 for in vitro diagnostic devices), please contact the Office of Compliance at (301) 594-4588. Additionally, for questions on the promotion and advertising of your device, please contact the Office of Compliance at (301) 594-4639. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). Other general information on your responsibilities under the Act may be obtained from the Division of Small Manufacturers Assistance at its toll-free number (800) 638-2041 or (301) 443-6597, or at its internet address "http://www.fda.gov/cdrh/dsma/dsmamain.html".

Sincerely yours,

Steven I. Gutman, M.D, M.B.A.

Director

Division of Clinical Laboratory Devices

Steven Butman

Office of Device Evaluation

Center for Devices and Radiological Health

				Page 1	of I
510(k) Number (if	f known):	K003106			
					1.500
Device Name:	InstaCheck BAR/BZO/	<sup>®</sup> Multi-Drug Screen Pa MTD Test	unel THC/COC/P	CP, MOR 2000/.	AMP, 
Indications For U					
2000/AMP, BA Tetrahydrocan Morphine Am	R/BZO/MTD (nabinol-9-car (phetamine, B	InstaCheck <sup>®</sup> Multi-le Test is an <i>in vitro</i> screboxylic acid, Cocaine arbiturates and its meand Methadone in hun	een test for the and its metabo etabolite - Secol	rapid detection olite - Benzoyleo oarbital, Benzod	of 11-nor-Δ´- cgonine, PCP liazepines and
TUC 11 nor-	A <sup>9</sup> _Tetrahydr	ocannabinol-9-carbox	vlic acid	50 ng/ml	
COC Benzoyl		ocannabinor y carbon,	,	300 ng/ml	
PCP Phency				25 ng/ml	
MOR Morphi				2000 ng/ml	
AMP Amphe				1000 ng/ml	
BAR Secobar				300 ng/ml	
BZO Oxazep				300 ng/ml	
MTD Methad				300 ng/ml	
		(Division Signatiff) Division of Changel	DOTALORY Devices K031010		
		510(k) Number			
(PLEASE DO NO	OT WRITE BELO	OW THIS LINE-CONTINU	E ON ANOTHER	PAGE IF NEEDED	<b>))</b>
		Concurrence of CDRH, C	Office of Device Ev	aluation (ODE)	
	./				
Prescription Use (Per 21 CFR 80		OR	Over-The-C	Counter Use	

(Optional Format 1-2-96)

			Page
510(k) Number (if	known):	16003106	
Device Name:			/PCP, MOR 300/AMP,
InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/AMP, BAR/BZO/MTD Test  The Forefront Diagnostics InstaCheck® Multi-Drug Screen Panel THC/COC/PCP, MOR 300/AMP, BAR/BZO/MTD Test is an in vitro screen test for the rapid detection of 11-nor-Δ°-Cetrahydrocannabinol-9-carboxylic acid, Cocaine and its metabolite - Benzoylecgonine, PCP, Morphine, Amphetamine, Barbiturates and its metabolite - Secobarbital, Benzodiazepines and its metabolite - Oxazepam, and Methadone in human urine at the following concentrations.  THC 11-nor-Δ°-Tetrahydrocannabinol-9-carboxylic acid 50 ng/ml 300 ng/ml 25 ng/ml  COC Benzoylecgonine 300 ng/ml  COC Phencyclidine 300 ng/ml  AMP Amphetamine 300 ng/ml  AMP Amphetamine 1000 ng/ml  BAR Secobarbital 300 ng/ml  BAR Secobarbital 300 ng/ml			
300/AMP, BAR Tetrahydrocan Morphine Am	/BZO/MTl nabinol-9-c nhetamine.	D Test is an <i>in vitro</i> screen test for th arboxylic acid, Cocaine and its meta Barbiturates and its metabolite - Sec	e rapid detection of 11-nor-2 bolite - Benzoylecgonine, PCP obarbital, Benzodiazepines and
THC 11 nor A	9 Totrahyo	drocannahinol-9-carboxylic acid	50 ng/ml
		il ocamia omor y car song no acce	<u> </u>
			9
			1000 ng/ml
			300 ng/ml
			300 ng/ml
_			300 ng/ml
		Jan Cooper	
		(Division Sign-Off) Division of Chinical Laboratory Dev  510(k) Number	vices
(PLEASE DO NO	T WRITE BE	ELOW THIS LINE-CONTINUE ON ANOTHER	R PAGE IF NEEDED)
		Concurrence of CDRH, Office of Device E	Evaluation (ODE)
Prescription Use (Per 21 CFR 801.	109)	OR Over-The	-Counter Use

(Optional Format 1-2-96)

			Page	1 of 1
510(k) Number (if k	(nown): 1400	73106		
Device Name:	InstaCheck <sup>®</sup> Multi-Drug BAR/BZO/MTD Test	g Screen Panel THC/	/COC/PCP, MOR	2000/MET,
Indications For Use	<b>2</b> :			
2000/MET, BAR Tetrahydrocann Morphine Meth	Diagnostics InstaCheck R/BZO/MTD Test is an abinol-9-carboxylic acid amphetamine, Barbitudte – Oxazepam, and Me	<i>in vitro</i> screen test t d, Cocaine and its rates and its metabo	for the rapid det metabolite - Bei olite - Secobarbi	nzoylecgonine, PCP, tal, Benzodiazepines
COC Benzoyle PCP Phencycl MOR Morphin MET Metham BAR Secobarb BZO Oxazepa MTD Methado The test kit is u	idine e ohetamine oital m	ualitative result an	300 25 2000 1000 300 300 300	ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml ng/ml
		(Division Sign-Off) Division of Clinical 510(k) Number	Laboratory Devices	
(PLEASE DO NO	T WRITE BELOW THIS LIN			
	Concurrence	e of CDRH, Office of De	evice Evaluation (O	D <b>⊢</b> )

Over-The-Counter Use \_\_\_\_\_

(Optional Format 1-2-96)

OR

Prescription Use (Per 21 CFR 801.109)

			Page _/ of _/_
510(k) Number (if k	nown):	K003106	
Device Name:		ck <sup>®</sup> Multi-Drug Screen Panel THC/0 O/MTD Test	COC/PCP, MOR 300/MET,
Indications For Use	);		
300/MET, BAR/ Tetrahydrocann	BZO/MT abinol-9-0	D Test is an <i>in vitro</i> screen test to carboxylic acid, Cocaine and its r mine Barbiturates and its metabo	een Panel THC/COC/PCP, MOR or the rapid detection of 11-nor- $\Delta^9$ -metabolite - Benzoylecgonine, PCP, lite - Secobarbital, Benzodiazepines rine at the following concentrations.
THC 11-nor-Δ COC Benzoyle PCP Phencycl MOR Morphin	<sup>9</sup> -Tetrahy cgonine idine e phetamine pital m	drocannabinol-9-carboxylic acid	50 ng/ml 300 ng/ml 25 ng/ml 300 ng/ml 1000 ng/ml 300 ng/ml 300 ng/ml 300 ng/ml
The test kit is u is not intended t	sed to obt for over th	ain a visual, quantative result and le counter sale to lay persons.	l is intended for professional use. I
		(Division Division 510(k) No	Can Coople Sign-Off) of Clinical Laboratory umber \( \square 00 3106 \)
(PLEASE DO NO	T WRITE B	ELOW THIS LINE-CONTINUE ON ANC	
Prescription Use (Per 21 CFR 801.	<u>/</u>	OR Ove	r-The-Counter Use (Optional Format 1-2-96)

It

			. •	Page	of
510(k) Number (if	known):	1003106			
Device Name:		k <sup>®</sup> Multi-Drug Screen Panel TI D/MTD Test	AC/COC/P	CP, MOR 300	
Indications For Us	e:				
BAR/BZO/MTI Tetrahydrocani Marrhina Barl	D Test is nabinol-9-ca biturates an	InstaCheck <sup>®</sup> Multi-Drug Scr an <i>in vitro</i> screen test fo arboxylic acid, Cocaine and d its metabolite - Secobarbita e in human urine at the follow	r tne rap its metabo al, Benzodi	olite - Benzoy iazepines and	lecgonine,
	A <sup>9</sup> -Tetrahyd ecgonine clidine ne bital am	rocannabinol-9-carboxylic ac		50 ng/n 300 ng/n 25 ng/n 300 ng/n 300 ng/n 300 ng/n	ml ml ml ml
IS NOT INCOLUCE		e counter sale to lay persons.			
		(Division Sign-Off Division of Clinica 510(K) Number	Laboratory	Devices 21010	
(PLEASE DO NO	OT WRITE BE	Concurrence of CDRH, Office of			
		Concurrence of ODIVIT, Office C	, 201100 EV	(000)	
Prescription Use (Per 21 CFR 801		OR	Over-The-C	Counter Use	

It

(Optional Format 1-2-96)